27 Jul

Biogen Presents Data from PRIME Study of Its Alzheimer’s Therapy

WRITTEN BY Margaret Patrick

PRIME study

On July 22, 2015, Biogen (BIIB) presented new data from the interim analysis of PRIME, the Phase 1b study of its investigational Alzheimer’s drug, aducanumab, or BIIB037, at the 2015 Alzheimer’s Association International Conference.

Alzheimer’s is a disease that affects the cognitive capabilities of individuals. Conducted on 166 patients suffering with prodromal or mild Alzheimer’s, PRIME is an ongoing Phase 1b randomized, double-blind, placebo-controlled study.

Biogen Presents Data from PRIME Study of Its Alzheimer’s Therapy

The above graph shows the current status of the BIIB037 in the FDA (US Federal Drug Administration) drug approval process. To learn more about the various approval phases, please read Drug Approval Process in the Biotechnology Industry.

In the context of Phase 1b of the clinical trial process, the PRIME study belongs to the first clinical testing phase of BIIB037. In this study, patients with similar demographic characteristics are randomly assigned different treatments under study. Groups of people receiving treatment—test groups—are then compared with those who receive no treatment—the control group. This is called a placebo-controlled study.

PRIME is also a double-blinded study, meaning that neither the patient nor the researcher knows if the patient belongs to the control group or to the test group. Randomized, double-blind, and placebo-controlled study is considered to be the gold standard in clinical trials. This standard is generally adopted by leading biotechnology companies such as Amgen (AMGN), Biogen, Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN) for testing the efficacy and safety of their pipeline drugs.

Results

Biogen presented mixed interim results from the PRIME study for its experimental Alzheimer’s drug, BIIB037. The study was conducted by administering 6 milligrams per kilogram of the patients’ weight for 54 weeks. Biogen uses two scales to measure the level of clinical decline associated with the Alzheimer’s Mini Mental State Examination, or MMSE, and clinical dementia rating sum of boxes, or CDR-SB. Though the drug seemed to slow the progression of Alzheimer’s, it failed to show a statistically significant improvement in cognition on the MMSE and CDR-SB scales.

Instead of directly investing in Biogen, investors can get diversified exposure to the company by investing in the iShares NASDAQ Biotechnology ETF (IBB). IBB has 7.48% of its total holdings in Biogen.

Latest articles

On October 17, Cannabis 2.0 legalized edibles, beverages, and concentrates in Canada. As the country waits for the benefits, is Cannabis 3.0 next?

Prohibition Partners expects that by 2024, the legal cannabis market could reach $103.9 billion and the medical cannabis market could reach $62.6 billion.

The cannabis sector was trading in the red today. MKM Partners lowered its revenue estimates for Canopy Growth (CGC) (WEED) and Aurora Cannabis (ACB).

Ford plans to unveil its crossover SUV, the Mach-E, on November 17. Ford committed $11.5 billion toward the electrification of its fleet through 2022.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it's illegal in Kansas. Even having a small amount is considered a crime.